Call Us:  +1.302.777.7774

CECON logo

Log in

Login to your account

Username *
Password *
Remember Me
Show More
Add this resume to contact form Yes No
Back to Search Result GO

Medicinal Chemist Expert for Drug Discovery and Preclinical Development

Technical Consultant #2283


  • Medicinal Chemistry
  • Drug Discovery
  • Preclinical Development
  • Synthetic Organic Chemistry
  • Intellectual Property Strategies


Independent Consultant, 2004-Present

  • Provide independent R&D (medicinal chemistry, drug discovery and preclinical development), business development and fundraising consulting services for established and start-up biotech, pharma and diagnostic companies.

Vice President, Research & Development, Managing Director, Molecular Imaging, (Subsidiary of Siemens), 2003-2004

  • Device, Software, Radiotracer and Diagnostic R&D. Led integrated medicinal chemistry, radiochemistry, physics, biology, probe discovery and development, microfluidics, hardware and software engineering functions.
  • President and Director for subsidiary, CTI Technologies, Inc.
  • Initiated development on new PET radiotracers for imaging Alzheimer's disease and cancer; managed multiple device, software and probe projects.

President and Chief Scientific Officer, Ceretek, LLC, 2000-2003

  • Lead all R&D, Business Development and fundraising activities. Full P&L responsibilities.
  • Developed substantial intellectual property portfolio covering novel receptors, assays and lead compounds.
  • Established and implemented the Company strategy of drug discovery and development targeting Lipid G-Protein Coupled Receptors (L-GPCRs) to identify novel therapeutics for cancer, immune, cardiovascular, ophthalmic and CNS disorders.
  • Led team that identified first novel subtype selective Edg1, Edg2, Edg4 and Edg7 antagonists.

Vice President, Scientific Affairs, Questcor Pharmaceuticals, Inc., 1997-2000

  • Led Questcor'9s antiinfective and cytoprotective preclinical research. Line management responsibility for biology, chemistry, informatics, and screening for the company.
  • Developed novel and successful antibacterial, antifungal and antiviral (Hepatitis C) programs certain of which are currently in preclinical or early clinical development.

Director of Chemistry, Synaptic Pharmaceutical Corp., 1991-1997

  • Directed the chemistry effort for successful projects including: alpha 1a antagonist project targeting Benign Prostatic Hyperplasia (BPH); alpha 1 and alpha 2 agonist projects for urinary incontinence, pain and glaucoma; novel NPY5 antagonists for treating obesity.

Senior Scientist, Medicinal Chemistry, Allergan, Inc., 1989-1990

  • Initiated and led the medicinal chemistry effort focusing on the discovery of novel alpha 2 agonists for the treatment of glaucoma.
  • Initiated the medicinal chemistry effort focusing on hypotensive lipids for the treatment of glaucoma.
  • Part of the project team that discovered LumiganTM, a novel prostaglandin that is marketed for the treatment of glaucoma.

Honors & Publications

  • Lawrence Livermore Labs Homeland Security Industry Advisory Group
  • Allergan Discovery Research Award
  • Sole or co-inventor of over 75 patents issued in the United States
  • Published over 45 peer-reviewed articles and book chapters.


  • Ph.D., Organic Chemistry, Texas A&M University
  • B.S., Chemistry, Stevens Institute of Technology
Back to Search Result GO